BELKIN Laser
BELKIN Laser
Glaucoma Care in the Blink of an Eye
 
BELKIN Laser presents a unique one-second glaucoma laser treatment, aimed at revolutionizing access to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient, all over the world.
BELKIN Laser: The New First-Line Treatment of Choice
Once-a-year Treatment
Rather than daily treatment
of eye drops
Patient Friendly
Non-invasive, non-contact,
instantaneous, & painless
Quickest Possible
A single press of a button,
one-second treatment
Simple to Perform
Automated, negligible
learning curve
Once-a-year Treatment
Rather than daily treatment
of eye drops
Patient Friendly
Non-invasive, non-contact,
instantaneous, & painless
Quickest Possible
A single press of a button,
one-second treatment
Simple to Perform
Automated, negligible
learning curve
Once-a-year Treatment
Rather than daily treatment
of eye drops
Patient Friendly
Non-invasive, non-contact,
instantaneous, & painless
Quickest Possible
A single press of a button,
one-second treatment
Simple to Perform
Automated, negligible
learning curve
 
Accessible to ALL ophthalmologists
as the first-line treatment of choice
BELKIN Laser: Compelling Commercial Opportunity
64 million people worldwide are estimated to suffer from glaucoma. This number is expected to reach 112 million patients by 2040. With traditional laser (LTP) offered only by specialists, glaucoma is a lucrative drug market, worth more than $4 Billion (~95% of the total glaucoma market).
BELKIN Laser is designed to make glaucoma laser treatment accessible through general ophthalmologists. This means that over 200,000 ophthalmologists worldwide will have the opportunity to offer their patients BELKIN Laser’s therapy as a first-line choice, representing a compelling target market for the BELKIN Laser treatment.
Asia
# Patients: 42 M
# Ophth.: 65,000
Europe
# Patients: 7 M
# Ophth.: 72,000
Africa
# Patients: 9 M
# Ophth.: 7,000
Latin America
# Patients: 7 M
# Ophth.: 34,000
N. America
# Patients: 3.5 M
# Ophth.: 27,000
Asia
# Patients: 42 M
# Ophth.: 65,000
Europe
# Patients: 7 M
# Ophth.: 72,000
Africa
# Patients: 9 M
# Ophth.: 7,000
Latin America
# Patients: 7 M
# Ophth.: 34,000
N. America
# Patients: 3.5 M
# Ophth.: 27,000
Asia
# Patients: 42 M
# Ophth.: 65,000
Europe
# Patients: 7 M
# Ophth.: 72,000
Africa
# Patients: 9 M
# Ophth.: 7,000
Latin America
# Patients: 7 M
# Ophth.: 34,000
N. America
# Patients: 3.5 M
# Ophth.: 27,000

# Patients: 70 M
# Ophth.: 212,000

# Patients: 70 M
# Ophth.: 212,000
 
 
BELKIN’s Social Impact

In developing countries, BELKIN Laser offers a unique solution for glaucoma patients, where medication is too expensive. In developed countries where medication is more affordable, only 50% of patients continue medical treatment after 1 year.
Both the measuring of IOP and its treatment by BELKIN Laser can be performed by every ophthalmologist and does not require expertise. Our ultimate goal is to have BELKIN Laser used by any medical personnel after a few minutes of training. The ease of use and the inexpensiveness of the BELKIN Laser treatment will solve the availability problem of glaucoma therapy everywhere in the world.
The humane, social, and economic consequences of its success are incalculable.
BELKIN’s Social Impact

In developing countries, BELKIN Laser offers a unique solution for glaucoma patients, where medication is too expensive. In developed countries where medication is more affordable, only 50% of patients continue medical treatment after 1 year.
Both the measuring of IOP and its treatment by BELKIN Laser can be performed by every ophthalmologist and does not require expertise. Our ultimate goal is to have BELKIN Laser used by any medical personnel after a few minutes of training. The ease of use and the inexpensiveness of the BELKIN Laser treatment will solve the availability problem of glaucoma therapy everywhere in the world.
The humane, social, and economic consequences of its success are incalculable.
 
 
 
Contact us to learn more
 
 
All rights reserved to Belkin Laser 2015 © | Design by: GLD/FRD | Built by: Livedns.co.il